GlassScriptPhysician profile
Jungyu E Jenke
NPI 1740935857
$505.38
in general payments reported to CMS, 2019-2025
16 companies · $9.26 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $228 · 2024: $94.63 · 2025: $9.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.81 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $48.49 | 2023-2024 | Rexulti |
| Alkermes, INC. | $46.21 | 2022-2024 | Vivitrol |
| Lundbeck LLC | $45.70 | 2023 | Rexulti |
| Tris Pharma INC | $44.66 | 2022-2023 | Dyanavel Xr |
| Abbvie INC. | $38.70 | 2023 | |
| Organon LLC | $38.36 | 2022-2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $30.81 | 2022 | |
| Indivior INC. | $27.40 | 2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $26.55 | 2022 | |
| Glaxosmithkline, LLC. | $24.17 | 2023 | Trelegy Ellipta |
| Noven Therapeutics, LLC | $23.10 | 2023 | Secuado |
| Novo Nordisk INC | $19.46 | 2023 | Ozempic |
| Seqirus USA INC | $14.16 | 2022 | |
| Lilly USA, LLC | $13.71 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.09 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jungyu Jenke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.